Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice

Circulation
Xiaojun LiPrediman K Shah

Abstract

Apolipoprotein (apo) A-I and apoA-I-mimetic peptides showed promise to prevent atherosclerosis development. Using a bypassed vein graft model in apoE-null mice, we evaluated the effects of oral or intraperitoneal administration of an apoA-I-mimetic peptide on evolving atherosclerotic lesions in the vein graft and compared such effects on the established atherosclerotic lesions in aortic sinus in the same mice. We used apoE-null mice in which a segment of inferior vena cava was grafted into the right carotid artery at 16 weeks of age. Native aortic atherosclerotic lesions (established atherosclerosis) and vein-graft atherosclerotic lesions (evolving atherosclerosis) were assessed 4 weeks after daily oral (0.3 mg/mL) or intraperitoneal (50 microg in 200 microL saline) administration of an apoA-I-mimetic peptide, D4F. Mice receiving saline or water without D4F served as controls. Both oral and intraperitoneal administration of D4F reduced vein-graft atherosclerotic (evolving lesions) plaque size by 43% and 42%, plaque lipid by 70% and 49%, and macrophage immunoreactivity by 63% and 62%, respectively, compared with controls. In contrast, D4F had no effect on the native aortic sinus atherosclerotic lesions (established lesions). Ora...Continue Reading

References

Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·A S PlumpJ L Breslow
Aug 1, 1994·The Journal of Clinical Investigation·C PásztyE M Rubin
Oct 20, 1998·The American Journal of Pathology·Y ZouQ Xu
Aug 10, 2000·The American Journal of Pathology·H DietrichQ Xu
Oct 4, 2002·Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology·Jennifer M Sarjeant, Marlene Rabinovitch
Feb 1, 2003·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Caroline F Thorn, Alexander S Whitehead
Nov 6, 2003·JAMA : the Journal of the American Medical Association·Steven E NissenRichard Kerensky

❮ Previous
Next ❯

Citations

Jan 15, 2008·Cellular and Molecular Life Sciences : CMLS·J S IsenbergD D Roberts
Apr 18, 2008·Current Atherosclerosis Reports·Roger YuAbbas Ardehali
Apr 29, 2010·Current Atherosclerosis Reports·Godfrey S GetzCatherine A Reardon
Mar 24, 2007·Current Treatment Options in Cardiovascular Medicine·Prediman K Shah
Oct 31, 2013·Journal of Medicinal Chemistry·Luke J LemanM Reza Ghadiri
Sep 23, 2006·Nature Clinical Practice. Cardiovascular Medicine·Mohamad NavabAlan M Fogelman
Jan 19, 2011·Nature Reviews. Cardiology·Emil M Degoma, Daniel J Rader
Mar 2, 2005·Nature Reviews. Drug Discovery·Patrick Linsel-Nitschke, Alan R Tall
Feb 2, 2008·Nature Reviews. Drug Discovery·Tisha Joy, Robert A Hegele
May 17, 2008·Nature Reviews. Drug Discovery·Alistair C Lindsay, Robin P Choudhury
Mar 24, 2010·Nature Reviews. Nephrology·Nosratola D VaziriAlan M Fogelman
Oct 4, 2006·Cell Research·Belinda A CutriStephen J Nicholls
Apr 2, 2011·Chemical Communications : Chem Comm·Anne BeilvertFrédéric Chaubet
Sep 24, 2005·The New England Journal of Medicine·M Dominique Ashen, Roger S Blumenthal
Aug 18, 2010·Antioxidants & Redox Signaling·Amir RezvanHanjoong Jo
May 22, 2010·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Nosratola D VaziriBernardo Rodriguez-Iturbe
Sep 30, 2010·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Geoffrey D WoolGodfrey S Getz
May 9, 2006·Current Opinion in Lipidology·Gm AnantharamaiahAlan M Fogelman
Jul 13, 2006·Current Opinion in Lipidology·Mohamad NavabAlan M Fogelman
Apr 17, 2010·Cardiology in Review·Courtney B ShermanWilliam H Frishman
Feb 22, 2008·Journal of Cardiovascular Pharmacology·Jonas Heilskov GraversenSøren Kragh Moestrup
Apr 18, 2009·Current Opinion in Lipidology·Godfrey S GetzCatherine A Reardon
Jul 18, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Mohamad NavabAlan M Fogelman
Jul 16, 2008·Journal of Lipid Research·Brian J Van LentenAlan M Fogelman
Jun 2, 2011·Circulation Journal : Official Journal of the Japanese Circulation Society·Satoshi ImaizumiSrinivasa T Reddy
Jul 17, 2008·Vascular Health and Risk Management·Navin K KapurRoger S Blumenthal
Dec 4, 2010·Vascular Health and Risk Management·Vibhuti SinghPrakash Deedwania
Apr 6, 2007·Internal Medicine·Shin-ichiro Miura, Keijiro Saku
Feb 28, 2013·International Urology and Nephrology·Georges KhoueiryJames Lafferty
Dec 24, 2005·Expert Opinion on Investigational Drugs·Srinivasa T ReddyAlan M Fogelman
Jun 10, 2008·Expert Opinion on Emerging Drugs·Rebecca L PollexRobert A Hegele
Mar 1, 2006·Expert Opinion on Investigational Drugs·Marta Marchesi, Cesare R Sirtori
Apr 3, 2012·Pharmacology & Therapeutics·Tisha R Joy
Sep 10, 2010·Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation·Nosratola D Vaziri
Nov 26, 2009·Bioorganic & Medicinal Chemistry Letters·Raffaele IngenitoElisabetta Bianchi
Feb 17, 2009·Endocrinology and Metabolism Clinics of North America·Peter P Toth
Mar 1, 2008·Trends in Cardiovascular Medicine·Mohamad NavabAlan M Fogelman
May 2, 2008·Journal of Clinical Lipidology·Mohamad NavabAlan M Fogelman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.